Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 3/20 | 0.56 |
| ▸ | HTR2C | P28335 | 2/20 | 0.56 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.52 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.52 |
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.46 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7053063 | 0.91 | HTR2C (0.54) | ADRA1AHTR2CDDB1CRBNPDE4A | |
| SCHEMBL2912686 | 0.90 | HTR2C (0.64) | ADRA1AHTR2CDDB1CRBNPDE4A | |
| SCHEMBL23705886 | 0.87 | HTR2C (0.58) | ADRA1AHTR2CDDB1CRBNDRD2 | |
| SCHEMBL14941711 | 0.84 | HTR2C (0.55) | ADRA1AHTR2CDDB1CRBNDRD2 | |
| SCHEMBL25048767 | 0.83 | PDE4A (0.50) | ADRA1AHTR2CDDB1CRBNPDE4A | |
| SCHEMBL9392309 | 0.83 | HTT (0.47) | ADRA1APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL25049286 | 0.81 | PDE4A (0.43) | ADRA1AHTR2CDDB1CRBNPDE4A | |
| SCHEMBL7005161 | 0.80 | PPARG (0.50) | ADRA1ACRBNPDE4APDE4BPDE4C | |
| SCHEMBL15492773 | 0.80 | PPARG (0.50) | ADRA1ACRBNPDE4APDE4BPDE4C | |
| SCHEMBL2044509 | 0.80 | ALDH1A1 (0.54) | DDB1CRBNPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030869-B2 | 5-membered heteroaryl carboxamide compounds for treatment of HBV | ASSEMBLY BIOSCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030869-B2 | 5-membered heteroaryl carboxamide compounds for treatment of HBV | ASSEMBLY BIOSCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240150324-A1 | 5-Membered Heteroaryl Carboxamide Compounds for Treatment of HBV | ASSEMBLY BIOSCIENCES, INC. | 2024-05-09 | — | — | US | disclosed |
| US-11560370-B1 | 5-membered heteroaryl carboxamide compounds for treatment of HBV | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-11560370-B1 | 5-membered heteroaryl carboxamide compounds for treatment of HBV | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| EP-0940387-B1 | PHENYLETHANOLAMINE COMPOUNDS USEFUL AS BETA3 AGONIST, PROCESS FOR PRODUCING THE SAME, AND INTERMEDIATES IN THE PRODUCTION OF THE SAME | MITSUBISHI PHARMA CORP (JP) | 2003-05-07 | — | — | EP | disclosed |
| CN-1090184-C | Heterocyclic compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-09-04 | — | — | CN | disclosed |
| EP-0736018-B1 | 4,5-DIARYLOXAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-07-05 | — | — | EP | disclosed |
| US-6069176-A | PHENYLETHANOLAMINE COMPOUNDS WITH A BETA-3 ADRENERGIC RECEPTOR STIMULATING EFFECT, USE AS A THERAPY FOR URINARY INCONTINENCE | MITSUBISHI-TOKYO PHARMACEUTICALS, INC. (JP) | 2000-05-30 | — | — | US | disclosed |
| US-6025375-A | INHIBITORY ACTIVITY ON PLATELET AGGREGATION, VASODILATING ACTIVITY, ANTIHYPERTENSIVE ACTIVITY OR THE LIKE AND ARE PROSTAGLANDIN I.SUB.2 AGONISTS, | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-02-15 | — | — | US | disclosed |
| CN-1046714-C | Diaryl oxazole derivative and its preparation method, application and pharmaceutical composition | FUJISAWA PHARMACEUTICAL CO (JP) | 1999-11-24 | — | — | CN | disclosed |
| CN-1229795-A | Heterocyclic compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 1999-09-29 | — | — | CN | disclosed |
| EP-0940387-A1 | PHENYLETHANOLAMINE COMPOUNDS USEFUL AS BETA3 AGONIST, PROCESS FOR PRODUCING THE SAME, AND INTERMEDIATES IN THE PRODUCTION OF THE SAME | TOKYO TANABE COMPANY LIMITED (JP) | 1999-09-08 | — | — | EP | disclosed |
| CN-1138328-A | Heterocyclic compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 1996-12-18 | — | — | CN | disclosed |
| EP-0736018-A1 | 4,5-DIARYLOXAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11560370-B1 | 5-membered heteroaryl carboxamide compounds for treatment of HBV | HCCS, HAVCR2, MAVS | ADRA1A 4722/4885HTR2C 3656/4885DDB1 162/4885 |
| US-20240150324-A1 | 5-Membered Heteroaryl Carboxamide Compounds for Treatment of HBV | HCCS, HAVCR2, MAVS | ADRA1A 4722/4885HTR2C 3656/4885DDB1 162/4885 |
| US-12030869-B2 | 5-membered heteroaryl carboxamide compounds for treatment of HBV | HCCS, HAVCR2, MAVS | ADRA1A 4722/4885HTR2C 3656/4885DDB1 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.